If You Invested in Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system (CNS) conditions. According to company disclosures, Relmada is advancing product candidates that aim to address significant unmet medical needs, with an emphasis on non-muscle invasive bladder cancer (NMIBC) and compulsivity-related neuropsychiatric disorders.

The company’s lead oncology program is NDV-01, described in multiple company press releases as a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) in development for the treatment of non-muscle invasive bladder cancer. NDV-01 is designed to enable Gem/Doce bladder retention and gradual drug release over about ten days, forming a soft matrix that increases local exposure while aiming to minimize systemic toxicity. Company materials state that NDV-01 is a ready-to-use formulation that can be administered in-office in less than ten minutes and does not require anesthesia or specialized equipment. NDV-01 is reported to be protected by patents through 2038.

Relmada reports that NDV-01 is being evaluated in an open-label, single-arm, single-center Phase 2 study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC). In company communications, the primary efficacy endpoints are described as safety and complete response rate at 12 months, with secondary endpoints including duration of response and event-free survival. Follow-up data released by the company describe high complete response rates at various time points and an absence of progression to muscle-invasive disease or radical cystectomy among enrolled patients, along with no Grade 3 or higher treatment-related adverse events and no treatment discontinuations due to adverse events in the reported cohorts.

Based on written feedback from the U.S. Food and Drug Administration (FDA) described by Relmada, the company is planning a Phase 3 registrational program for NDV-01 in two NMIBC settings. For high-grade, 2nd-line BCG-unresponsive NMIBC with carcinoma in situ (CIS), FDA feedback indicates that a single-arm, open-label trial in a refractory population is an appropriate registrational approach, with a primary endpoint of complete response rate at any time and key secondary endpoints including duration of response, assessed by cystoscopy, cytology, and biopsy per protocol. For intermediate-risk NMIBC in the adjuvant setting, FDA communications cited by the company support an open-label randomized-to-observation design with disease-free survival as the primary endpoint and duration of response as a key secondary endpoint. Relmada has stated that it anticipates initiating both registrational trials in the first half of 2026, subject to ongoing regulatory interactions.

In addition to NDV-01, Relmada highlights sepranolone as another lead candidate. Company disclosures describe sepranolone as a synthetic isoallopregnanolone that selectively modulates GABAA receptors by antagonizing allopregnanolone (ALLO) without disrupting GABA signaling. Relmada states that sepranolone targets disorders linked to excess GABAergic activity, including Prader-Willi syndrome (PWS), Tourette syndrome, and obsessive-compulsive disorder (OCD). According to the company, more than 335 patients have been treated with sepranolone in clinical trials with what is described as an excellent safety profile. Relmada has communicated plans to initiate a Phase 2 proof-of-concept clinical trial of sepranolone in PWS.

Company materials characterize Prader-Willi syndrome as a rare genetic disorder caused by chromosomal deletions on chromosome 15, associated with neurodevelopmental and behavioral complications. Public statements from Relmada note that global prevalence is estimated in the hundreds of thousands of patients and that current treatments address symptoms rather than the underlying neurobehavioral pathology. Relmada positions sepranolone as a potential therapy for compulsivity-related features of PWS and other conditions linked to excess GABAergic activity.

Relmada describes itself in recent press releases and SEC filings as a clinical-stage biotechnology company advancing “transformative therapies for oncology and central nervous system indications” or “oncology-related and central nervous system indications.” The company’s disclosures emphasize that NDV-01 and sepranolone are in mid-stage clinical development and are intended to address patient populations with limited existing treatment options, particularly in NMIBC and rare neurodevelopmental disorders.

Relmada Therapeutics is incorporated in Nevada, as indicated in its SEC filings, and lists its principal offices in Coral Gables, Florida. Its common stock, with a par value of $0.001 per share, trades on the Nasdaq Capital Market under the symbol RLMD. The company has reported that it remains in compliance with Nasdaq’s continued listing requirements following a period in which it received a minimum bid price deficiency notice and subsequently regained compliance.

Relmada’s public communications also reference its capital markets activities. For example, the company has disclosed an underwritten offering of common stock and pre-funded warrants, with stated gross proceeds of approximately $100 million before expenses, intended to support working capital, clinical studies required for regulatory approvals, further development of its product candidates, and other general corporate purposes. SEC filings describe the terms of this offering, including the issuance of pre-funded warrants, the role of underwriters, and the use of a shelf registration statement on Form S-3.

Overall, based on the company’s own descriptions in press releases and SEC filings, Relmada Therapeutics centers its strategy on advancing NDV-01 for non-muscle invasive bladder cancer through Phase 2 and planned Phase 3 studies, while also preparing sepranolone for Phase 2 evaluation in Prader-Willi syndrome and other compulsivity-related CNS conditions. Investors and observers typically look to Relmada’s clinical data updates, regulatory interactions, and financing disclosures to understand the development trajectory and risk profile of RLMD stock.